Cargando…
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
BACKGROUND: Gemcitabine is a frequently used chemotherapeutic agent but its effects on the immune system are incompletely understood. Recently, the randomized NVALT19-trial revealed that maintenance gemcitabine after first-line chemotherapy significantly prolonged progression-free survival (PFS) com...
Autores principales: | Dammeijer, Floris, De Gooijer, Cornedine J., van Gulijk, Mandy, Lukkes, Melanie, Klaase, Larissa, Lievense, Lysanne A., Waasdorp, Cynthia, Jebbink, Merel, Bootsma, Gerben P., Stigt, Jos A., Biesma, Bonne, Kaijen-Lambers, Margaretha E.H., Mankor, Joanne, Vroman, Heleen, Cornelissen, Robin, Baas, Paul, Van der Noort, Vincent, Burgers, Jacobus A., Aerts, Joachim G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910686/ https://www.ncbi.nlm.nih.gov/pubmed/33516644 http://dx.doi.org/10.1016/j.ebiom.2020.103160 |
Ejemplares similares
-
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
por: Lau, Sai Ping, et al.
Publicado: (2020) -
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
por: van Gulijk, Mandy, et al.
Publicado: (2018) -
Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022) -
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects
por: Lievense, Lysanne A., et al.
Publicado: (2022) -
Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
por: Mahaweni, Niken M., et al.
Publicado: (2013)